Abstract:Metastasis is the main cause of death in cancer patients. The efficacy of pharmacological therapy for cancer is limited by the heterogeneous nature of cancer cells and the lack of knowledge of microenvironments in metastasis. Evidence has shown that activated platelets possess both tumor-homing and metastasis-targeting properties via intrinsic cell adhesion molecules on platelets, and malaria protein VAR2CSA is able to specifically bind to oncofetal chondroitin sulfate, which is overexpressed on cancer cells with both epithelial and mesenchymal phenotypes. Inspired by these mechanisms, we developed a recombinant VAR2CSA peptide (rVAR2)-modified activated platelet-mimicking nanoparticles (rVAR2-PM/PLGA-ss-HA) by coating the surface of disulfide-containing biodegradable PLGA conjugate nanoparticles (PLGA-ss-HA) with an activated platelet membrane. The results demonstrated that the engineered 122 nm rVAR2-PM/PLGA-ss-HA inherited the innate properties of the activated platelet membrane and achieved enhanced homing to both primary and metastatic foci. The nanoparticles were endocytosed and responded to a high intracellular concentration of reduced glutathione, resulting in nanoparticle disintegration and the release of chemotherapeutic drugs to kill tumor cells. Thus, rVAR2-decorated activated platelet-targeting nanoparticles with controlled drug release provide a promising drug delivery strategy for efficient treatment of primary and metastatic cancer.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acsami.1c02581?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acsami.1c02581</a>.Examination of the scrambled peptide (Scr) targeting ability; structural characterization of DSPE-PEG-rVAR2; presence of PM proteins on rVAR2-PM/PLGA-ss-HA nanoparticles; in vitro 264.7 cell uptake assay; tumor weight of the excised tumors; and hemocompatibility assay (<a class="ext-link" href="/doi/suppl/10.1021/acsami.1c02581/suppl_file/am1c02581_si_001.pdf">PDF</a>)This article has not yet been cited by other publications.

Platelet Membrane-Coated and VAR2CSA Malaria Protein-Functionalized Nanoparticles for Targeted Treatment of Primary and Metastatic Cancer